Radiation seeds may be enough for prostate cancer
Key points
- Implanting tiny radioactive "seeds" in the prostate, a treatment called brachytherapy, may be all that is needed to combat low-risk forms of prostate cancer, new research suggests.
- Additional treatments, such as radiation from an external source, known as external beam radiotherapy (EBRT), or reducing testosterone levels, known as androgen deprivation therapy (ADT), may only be necessary for severe forms of the disease.
- "The most important part of the work is that low-risk patients do not require (EBRT) or ADT," Dr.
- "Unfortunately, a high percentage of low-risk patients unnecessarily receive ADT and some centers recommend supplemental (EBRT) for all patients" regardless of prostate cancer severity, he commented.
Implanting tiny radioactive "seeds" in the prostate, a treatment called brachytherapy, may be all that is needed to combat low-risk forms of prostate cancer, new research suggests.
Additional treatments, such as radiation from an external source, known as external beam radiotherapy (EBRT), or reducing testosterone levels, known as androgen deprivation therapy (ADT), may only be necessary for severe forms of the disease. The findings appear in the International Journal of Radiation Oncology, Biology, Physics.
"The most important part of the work is that low-risk patients do not require (EBRT) or ADT," Dr. Gregory S. Merrick from Wheeling Hospital, in West Virginia told Reuters Health.
"Unfortunately, a high percentage of low-risk patients unnecessarily receive ADT and some centers recommend supplemental (EBRT) for all patients" regardless of prostate cancer severity, he commented.
Based on preliminary findings, "it also appears that (EBRT) will be proven unnecessary in intermediate-risk patients and once again, ADT is unnecessary in intermediate-risk patients," Merrick said.
Merrick and colleagues evaluated the benefit of adding EBRT and/or ADT to seed therapy in 227 patients with low-risk prostate cancer, 251 with intermediate-risk prostate cancer, and 190 with high-risk prostate cancer.
As noted, the authors found no evidence that adding EBRT or ADT to seed therapy improved survival in the low-risk group of patients and probably not in the intermediate-risk group either.
For high-risk patients, however, these added therapies did seem to offer a benefit beyond that achieved with seed therapy and the researchers plan to look at this issue further in an upcoming study.
SOURCE: International Journal of Radiation Oncology*Biology*Physics, January 1, 2005.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNew biomarker identified in breast and prostate cancers holds promise for treating disease
Cedars-Sinai researchers have identified a novel genetic biomarker responsible for the progression of many breast and prostate cancers. The finding could bolster efforts to better identify patients who respond to…
8 August 2015
NewsDoes radiation from X-rays and CT scans really cause cancer?
In recent years, there has been widespread media coverage of studies purporting to show that radiation from X-rays, CT scans and other medical imaging causes cancer. But such studies have serious flaws, including their…
1 July 2015
NewsAn immune system marker for therapy-resistant prostate cancer
You are a patient who has just been treated for a serious illness but neither you nor your doctor knows how likely it is that you - in comparison with other patients - will actually be helped by the treatment. This is…
